Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 139

Similar articles for PubMed (Select 23664099)

1.

Design, synthesis, quantum chemical studies and biological activity evaluation of pyrazole-benzimidazole derivatives as potent Aurora A/B kinase inhibitors.

Zheng Y, Zheng M, Ling X, Liu Y, Xue Y, An L, Gu N, Ji M.

Bioorg Med Chem Lett. 2013 Jun 15;23(12):3523-30. doi: 10.1016/j.bmcl.2013.04.039. Epub 2013 Apr 25. Erratum in: Bioorg Med Chem Lett. 2013 Aug 1;23(15):4471. Jin, Min [corrected to Ji, Min].

PMID:
23664099
2.

Synthesis and quantum chemical studies of new 4-aminoquinazoline derivatives as Aurora A/B kinase inhibitors.

Zheng M, Zheng Y, Xue Y, Liu Y, An L, Zhang L, Ji M, Xue B, Wu X, Gong X, Gu N, Zhan X.

Chem Biol Drug Des. 2013 Mar;81(3):399-407. doi: 10.1111/cbdd.12089. Epub 2012 Dec 26.

PMID:
23279802
3.

Aurora isoform selectivity: design and synthesis of imidazo[4,5-b]pyridine derivatives as highly selective inhibitors of Aurora-A kinase in cells.

Bavetsias V, Faisal A, Crumpler S, Brown N, Kosmopoulou M, Joshi A, Atrash B, Pérez-Fuertes Y, Schmitt JA, Boxall KJ, Burke R, Sun C, Avery S, Bush K, Henley A, Raynaud FI, Workman P, Bayliss R, Linardopoulos S, Blagg J.

J Med Chem. 2013 Nov 27;56(22):9122-35. doi: 10.1021/jm401115g. Epub 2013 Nov 6.

4.

Click approach to the discovery of 1,2,3-triazolylsalicylamides as potent Aurora kinase inhibitors.

Song D, Park Y, Yoon J, Aman W, Hah JM, Ryu JS.

Bioorg Med Chem. 2014 Sep 1;22(17):4855-66. doi: 10.1016/j.bmc.2014.06.047. Epub 2014 Jun 30.

PMID:
25042560
5.

Design, synthesis and bioevaluation of N-trisubstituted pyrimidine derivatives as potent aurora A kinase inhibitors.

Luo Y, Deng YQ, Wang J, Long ZJ, Tu ZC, Peng W, Zhang JQ, Liu Q, Lu G.

Eur J Med Chem. 2014 May 6;78:65-71. doi: 10.1016/j.ejmech.2014.03.027. Epub 2014 Mar 12.

PMID:
24681066
6.

Design, synthesis and bioevaluation of dihydropyrazolo[3,4-b]pyridine and benzo[4,5]imidazo[1,2-a]pyrimidine compounds as dual KSP and Aurora-A kinase inhibitors for anti-cancer agents.

Fu RG, You QD, Yang L, Wu WT, Jiang C, Xu XL.

Bioorg Med Chem. 2010 Nov 15;18(22):8035-43. doi: 10.1016/j.bmc.2010.09.020. Epub 2010 Sep 16.

PMID:
20934346
7.

Design and synthesis of 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles and pyrazolo[3,4-b]pyridines for Aurora-A kinase inhibitors.

Shi J, Xu G, Zhu W, Ye H, Yang S, Luo Y, Han J, Yang J, Li R, Wei Y, Chen L.

Bioorg Med Chem Lett. 2010 Jul 15;20(14):4273-8. doi: 10.1016/j.bmcl.2010.04.083. Epub 2010 May 10.

PMID:
20621733
8.

Discovery of 7-aryl-substituted (1,5-naphthyridin-4-yl)ureas as aurora kinase inhibitors.

Defaux J, Antoine M, Le Borgne M, Schuster T, Seipelt I, Aicher B, Teifel M, Günther E, Gerlach M, Marchand P.

ChemMedChem. 2014 Jan;9(1):217-32. doi: 10.1002/cmdc.201300384. Epub 2013 Nov 24.

PMID:
24273104
9.

A thienopyrimidine derivative induces growth inhibition and apoptosis in human cancer cell lines via inhibiting Aurora B kinase activity.

Li J, Hu H, Lang Q, Zhang H, Huang Q, Wu Y, Yu L.

Eur J Med Chem. 2013 Jul;65:151-7. doi: 10.1016/j.ejmech.2013.04.058. Epub 2013 May 4.

PMID:
23707920
10.

Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.

Howard S, Berdini V, Boulstridge JA, Carr MG, Cross DM, Curry J, Devine LA, Early TR, Fazal L, Gill AL, Heathcote M, Maman S, Matthews JE, McMenamin RL, Navarro EF, O'Brien MA, O'Reilly M, Rees DC, Reule M, Tisi D, Williams G, Vinković M, Wyatt PG.

J Med Chem. 2009 Jan 22;52(2):379-88. doi: 10.1021/jm800984v.

PMID:
19143567
11.

Discovery of azabenzimidazole derivatives as potent, selective inhibitors of TBK1/IKKε kinases.

Wang T, Block MA, Cowen S, Davies AM, Devereaux E, Gingipalli L, Johannes J, Larsen NA, Su Q, Tucker JA, Whitston D, Wu J, Zhang HJ, Zinda M, Chuaqui C.

Bioorg Med Chem Lett. 2012 Mar 1;22(5):2063-9. doi: 10.1016/j.bmcl.2012.01.018. Epub 2012 Jan 14.

PMID:
22305584
12.

SERS and MD simulation studies of a kinase inhibitor demonstrate the emergence of a potential drug discovery tool.

Karthigeyan D, Siddhanta S, Kishore AH, Perumal SS, Ågren H, Sudevan S, Bhat AV, Balasubramanyam K, Subbegowda RK, Kundu TK, Narayana C.

Proc Natl Acad Sci U S A. 2014 Jul 22;111(29):10416-21. doi: 10.1073/pnas.1402695111. Epub 2014 Jun 27.

13.

Discovery of 4-aminoquinazoline--urea derivatives as Aurora kinase inhibitors with antiproliferative activity.

Cai J, Li L, Hong KH, Wu X, Chen J, Wang P, Cao M, Zong X, Ji M.

Bioorg Med Chem. 2014 Nov 1;22(21):5813-23. doi: 10.1016/j.bmc.2014.09.029. Epub 2014 Sep 19.

PMID:
25270403
14.

Synthesis, biological evaluation, and molecular docking studies of N,1,3-triphenyl-1H-pyrazole-4-carboxamide derivatives as anticancer agents.

Li X, Lu X, Xing M, Yang XH, Zhao TT, Gong HB, Zhu HL.

Bioorg Med Chem Lett. 2012 Jun 1;22(11):3589-93. doi: 10.1016/j.bmcl.2012.04.066. Epub 2012 Apr 21.

PMID:
22572580
15.

Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors.

Ramurthy S, Subramanian S, Aikawa M, Amiri P, Costales A, Dove J, Fong S, Jansen JM, Levine B, Ma S, McBride CM, Michaelian J, Pick T, Poon DJ, Girish S, Shafer CM, Stuart D, Sung L, Renhowe PA.

J Med Chem. 2008 Nov 27;51(22):7049-52. doi: 10.1021/jm801050k.

PMID:
18942827
16.

Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines.

Baldini E, Tuccilli C, Prinzi N, Sorrenti S, Antonelli A, Gnessi L, Morrone S, Moretti C, Bononi M, Arlot-Bonnemains Y, D'Armiento M, Ulisse S.

Endocr Relat Cancer. 2014 Oct;21(5):797-811. doi: 10.1530/ERC-14-0299. Epub 2014 Jul 29.

PMID:
25074669
17.

Discovery of (7-aryl-1,5-naphthyridin-2-yl)ureas as dual inhibitors of ERK2 and Aurora B kinases with antiproliferative activity against cancer cells.

Defaux J, Antoine M, Logé C, Le Borgne M, Schuster T, Seipelt I, Aicher B, Teifel M, Günther E, Gerlach M, Marchand P.

Bioorg Med Chem Lett. 2014 Aug 15;24(16):3748-52. doi: 10.1016/j.bmcl.2014.06.078. Epub 2014 Jul 3.

PMID:
25022204
18.

Facile identification of dual FLT3-Aurora A inhibitors: a computer-guided drug design approach.

Chang Hsu Y, Ke YY, Shiao HY, Lee CC, Lin WH, Chen CH, Yen KJ, Hsu JT, Chang C, Hsieh HP.

ChemMedChem. 2014 May;9(5):953-61. doi: 10.1002/cmdc.201300571. Epub 2014 Mar 24.

PMID:
24665000
19.

The dual Aurora kinase inhibitor ZM447439 prevents anaplastic thyroid cancer cell growth and tumorigenicity.

Baldini E, Tuccilli C, Prinzi N, Sorrenti S, Antonelli A, Gnessi L, Catania A, Moretti C, Mocini R, Carbotta G, Morrone S, Persechino S, Redler A, De Antoni E, D' Armiento M, Ulisse S.

J Biol Regul Homeost Agents. 2013 Jul-Sep;27(3):705-15.

PMID:
24152827
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk